NALINI AGARWAL: Open Payments
NPI 1073603213 · SOUTHGATE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$403 in 14 payments from 11 companies in 2025. Trend: 2023 $17 · 2024 $346 · 2025 $403
Food & beverage: $403
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $120 |
| Janssen Pharmaceuticals, Inc | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| ABBVIE INC. | 1 | $28 |
| Sage Therapeutics, LLC | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Neurocrine BioSciences, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $17 |
Products named: CAPLYTA, INVEGA SUSTENNA, UZEDY, VRAYLAR, ZURZUVAE, Qelbree, INGREZZA, Auvelity.
Industry payments across MI — which companies pay providers there.
